コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 0.008 for the reduction; hazard ratio, 0.11; 95 percent confidence interval, 0.02 to 0.81; P=0.03).
2 se breasts on mammography (difference, 0.11; 95 percent confidence interval, 0.04 to 0.18; P=0.003),
3 l or perimenopausal women (difference, 0.15; 95 percent confidence interval, 0.05 to 0.24; P=0.002).
4 ifference in the area under the curve, 0.15; 95 percent confidence interval, 0.05 to 0.25; P=0.002),
5 iving placebo (relative risk of death, 0.20; 95 percent confidence interval, 0.06 to 0.70; P=0.01).
6 standard-therapy group (hazard ratio, 0.20; 95 percent confidence interval, 0.06 to 0.71; P=0.006).
7 bal ability (adjusted mean difference, 0.60; 95 percent confidence interval, 0.07 to 1.13), although
8 who were given placebo (hazard ratio, 0.25; 95 percent confidence interval, 0.08 to 0.75; P=0.008).
9 ent of the time (adjusted hazard ratio, 0.3; 95 percent confidence interval, 0.1 to 0.6, adjusted for
10 t)--and decreased to 0.14 percent per month (95 percent confidence interval, 0.11 to 0.18 percent) af
11 9 events, respectively; relative risk, 0.27; 95 percent confidence interval, 0.11 to 0.67; P=0.005).
12 0.80; P=0.002) and blacks (odds ratio, 0.32; 95 percent confidence interval, 0.12 to 0.89; P=0.03) wh
14 mproved survival (adjusted risk ratio, 0.28; 95 percent confidence interval, 0.14 to 0.55; P<0.01).
15 ue), 0.31 for physician-diagnosed emphysema (95 percent confidence interval, 0.18 to 0.52; P for line
16 p; relative risk of chronic rejection, 0.38; 95 percent confidence interval, 0.18 to 0.82; P=0.01) an
17 3 percent, respectively; hazard ratio, 0.39; 95 percent confidence interval, 0.18 to 0.84; P=0.01), a
18 3 percent, respectively; hazard ratio, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.02).
19 atio for aspirin relative to warfarin, 0.46; 95 percent confidence interval, 0.23 to 0.90; P=0.02), m
20 percent; P=0.05; adjusted odds ratio, 0.47; 95 percent confidence interval, 0.23 to 0.98; P=0.04).
22 clitaxel-eluting stent (relative risk, 0.39; 95 percent confidence interval, 0.26 to 0.59; P<0.001).
23 ; P=0.09), progression to WHO stage 4 (0.50; 95 percent confidence interval, 0.28 to 0.90; P=0.02), o
24 phamide and placebo groups was 2.53 percent (95 percent confidence interval, 0.28 to 4.79 percent), f
25 closporine and placebo groups: 0.44 episode (95 percent confidence interval, 0.31 to 0.62) vs. 0.46 e
26 ean difference for receptive language, 0.82; 95 percent confidence interval, 0.31 to 1.33; and adjust
27 and 0.50 for spirometrically detected COPD (95 percent confidence interval, 0.32 to 0.79; P for line
28 tion in the risk of CHD (hazard ratio, 0.50; 95 percent confidence interval, 0.32 to 0.79; P=0.003).
29 ce interval, 0.31 to 0.62) vs. 0.46 episode (95 percent confidence interval, 0.33 to 0.64) per patien
30 ) in the placebo group (relative risk, 0.53; 95 percent confidence interval, 0.33 to 0.87; P=0.01).
32 nstrated that both whites (odds ratio, 0.55; 95 percent confidence interval, 0.38 to 0.80; P=0.002) a
33 72 in the placebo group (hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.81; P=0.003).
34 ancer (40 vs. 70 events; hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.83; absolute r
35 ent) in the control group (risk ratio, 0.68; 95 percent confidence interval, 0.38 to 1.22; P=0.20).
37 standard-therapy group (hazard ratio, 0.65; 95 percent confidence interval, 0.40 to 1.06; P=0.08).
38 atio for local or regional recurrence, 0.61; 95 percent confidence interval, 0.41 to 0.91; P=0.01).
39 t 90 days by 41 percent (hazard ratio, 0.59; 95 percent confidence interval, 0.43 to 0.81; P=0.001).
40 in the control group died (risk ratio, 0.68; 95 percent confidence interval, 0.44 to 1.05; P=0.08).
41 rresponding figures for the girls were 0.62 (95 percent confidence interval, 0.46 to 0.82; P=0.001) a
42 tures (64 vs. 97 events; hazard ratio, 0.65; 95 percent confidence interval, 0.47 to 0.89; absolute r
43 of celecoxib twice a day (risk ratio, 0.55; 95 percent confidence interval, 0.48 to 0.64; P<0.001).
44 0 percent vs. 30 percent; hazard ratio 0.64; 95 percent confidence interval, 0.48 to 0.85; P<0.002).
45 odds ratios for frequent symptoms were 0.67 (95 percent confidence interval, 0.48 to 0.93) for a BMI
46 onfidence interval, 0.63 to 0.80), and 0.58 (95 percent confidence interval, 0.50 to 0.67), respectiv
47 percent vs. 55 percent; hazard ratio, 0.63; 95 percent confidence interval, 0.51 to 0.77; P<0.001).
48 rcent vs. 31.1 percent; relative risk, 0.71; 95 percent confidence interval, 0.51 to 0.98; P=0.04).
49 he acquired immunodeficiency syndrome (0.73; 95 percent confidence interval, 0.51 to 1.04; P=0.09), p
50 imilarly reduced (adjusted odds ratio, 0.66; 95 percent confidence interval, 0.52 to 0.83; P<0.001).
51 st quartile was 0.66 for chronic bronchitis (95 percent confidence interval, 0.52 to 0.85; P<0.001 fo
53 ix months of age (0.88 per 100,000 children; 95 percent confidence interval, 0.52 to 1.39 per 100,000
54 quartile for total homocysteine, were 1.96 (95 percent confidence interval, 0.52 to 3.41), 3.24 (0.9
55 urvival (hazard ratio for progression, 0.66; 95 percent confidence interval, 0.53 to 0.81; P<0.001).
56 ent) in the control group (risk ratio, 0.72; 95 percent confidence interval, 0.54 to 0.95; P=0.01).
57 ABG relative to stent implantation was 0.64 (95 percent confidence interval, 0.56 to 0.74) for patien
59 or the donepezil group (hazard ratio, 0.80; 95 percent confidence interval, 0.57 to 1.13; P=0.42) du
60 , or progression to stage 3 or higher (0.72; 95 percent confidence interval, 0.58 to 0.90; P=0.003).
61 of celecoxib twice a day (risk ratio, 0.67; 95 percent confidence interval, 0.59 to 0.77; P<0.001) a
64 rall survival (hazard ratio for death, 0.75; 95 percent confidence interval, 0.60 to 0.93; P=0.009; f
66 nterior descending coronary artery and 0.76 (95 percent confidence interval, 0.60 to 0.96) for patien
67 disability progression (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P=0.02).
68 up (hazard ratio for disease or death, 0.78; 95 percent confidence interval, 0.61 to 0.99; P=0.04), b
69 nt confidence interval, 0.80 to 0.98), 0.71 (95 percent confidence interval, 0.63 to 0.80), and 0.58
70 isk of ischemic stroke (relative risk, 0.76; 95 percent confidence interval, 0.63 to 0.93; P=0.009) a
71 vival was not (hazard ratio for death, 0.84; 95 percent confidence interval, 0.65 to 1.09; P=0.19).
72 iated with a 1 SD increase in BMI were 0.76 (95 percent confidence interval, 0.66 to 0.87; P<0.001) a
73 ercent vs. 9.5 percent; relative risk, 0.80; 95 percent confidence interval, 0.66 to 0.98), as was th
74 t was 0.77 on our test of general cognition (95 percent confidence interval, 0.67 to 0.88) and 0.81 o
76 ative reduction in risk (hazard ratio, 0.78; 95 percent confidence interval, 0.69 to 0.89; P<0.001).
77 with the placebo group (relative risk, 0.83; 95 percent confidence interval, 0.69 to 0.99; P=0.04), o
78 als and general hospitals was similar (0.89; 95 percent confidence interval, 0.69 to 1.15; P=0.39), b
79 0.78 to 0.95) and 81.6 percent sensitivity (95 percent confidence interval, 0.70 to 0.90) in discrim
82 y hospitals than in general hospitals (0.84; 95 percent confidence interval, 0.72 to 0.99; P=0.05).
83 had a hazard ratio of 0.88 for hip fracture (95 percent confidence interval, 0.72 to 1.08), 0.90 for
84 e in the warfarin group (hazard ratio, 1.04; 95 percent confidence interval, 0.73 to 1.48; P=0.83).
85 performance over a two-year period was 0.85 (95 percent confidence interval, 0.74 to 0.98) among mode
86 d relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) an
87 cardiovascular causes (relative risk, 0.95; 95 percent confidence interval, 0.74 to 1.22; P=0.68).
88 in the vitamin E group (hazard ratio, 1.02; 95 percent confidence interval, 0.74 to 1.41; P=0.91) or
89 cent versus 68 percent (relative risk, 0.90; 95 percent confidence interval, 0.75 to 1.08; P=0.26).
90 ercent among 16-year-olds (rate ratio, 0.80; 95 percent confidence interval, 0.76 to 0.85), and 16 pe
92 9 percent with placebo (relative risk, 0.88; 95 percent confidence interval, 0.77 to 0.998; P=0.046).
93 ptide detector had 88.2 percent specificity (95 percent confidence interval, 0.78 to 0.95) and 81.6 p
94 the second through fifth quintiles were 1.7 (95 percent confidence interval, 0.8 to 3.5), 1.8 (95 per
95 percent among 17-year-olds (rate ratio 0.84; 95 percent confidence interval, 0.80 to 0.87), relative
96 ratios for death in the hospital were 0.88 (95 percent confidence interval, 0.80 to 0.98), 0.71 (95
97 h aspirin of 9 percent (relative risk, 0.91; 95 percent confidence interval, 0.80 to 1.03; P=0.13).
98 of hemorrhagic stroke (relative risk, 1.24; 95 percent confidence interval, 0.82 to 1.87; P=0.31).
99 ercent among 15-year-olds (rate ratio, 0.89; 95 percent confidence interval, 0.83 to 0.94), 20 percen
100 h placebo plus aspirin (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P=0.22).
102 nts (533 vs. 553 events; hazard ratio, 0.95; 95 percent confidence interval, 0.84 to 1.07), and it re
103 nt in the placebo group (hazard ratio, 0.95; 95 percent confidence interval, 0.84 to 1.08; P=0.41).
104 myocardial infarction (relative risk, 1.02; 95 percent confidence interval, 0.84 to 1.25; P=0.83) or
105 rcent and 17.9 percent (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.995; P=0.04),
106 t in the placebo group (relative risk, 0.97; 95 percent confidence interval, 0.86 to 1.06; P=0.52), a
108 cebo (168 and 154 cases; hazard ratio, 1.08; 95 percent confidence interval, 0.86 to 1.34; P=0.51), a
109 curve for the autoantibody signature, 0.93; 95 percent confidence interval, 0.88 to 0.97; area under
110 66 percent vs. 63 percent; odds ratio, 1.14; 95 percent confidence interval, 0.88 to 1.48; P=0.32).
111 03 to 1.07) and black men (risk ratio, 0.95; 95 percent confidence interval, 0.89 to 1.00), as compar
112 e low-dose celecoxib group (risk ratio, 1.1; 95 percent confidence interval, 0.9 to 1.3; P=0.5) and 2
113 rcent confidence interval, 0.8 to 3.5), 1.8 (95 percent confidence interval, 0.9 to 3.7), 2.5 (95 per
114 twice daily (2.3 percent; hazard ratio, 2.3; 95 percent confidence interval, 0.9 to 5.5) and with 23
115 .5 percent with placebo (relative risk, 1.2; 95 percent confidence interval, 0.91 to 1.59; P=0.20) an
116 ly lower in patients than in controls (0.96; 95 percent confidence interval, 0.92 to 0.99; P=0.01).
117 e DrotAA group; P=0.34; relative risk, 1.08; 95 percent confidence interval, 0.92 to 1.28) or in in-h
119 zation for colon cancer (hazard ratio, 1.02; 95 percent confidence interval, 0.95 to 1.09) but was hi
120 nt confidence interval, 0.99 to 1.84), 1.29 (95 percent confidence interval, 0.96 to 1.72), and 2.37
121 ercent and 1.3 percent (relative risk, 1.25; 95 percent confidence interval, 0.97 to 1.61 percent; P=
122 idence interval, 0.999 to >0.999) and 0.997 (95 percent confidence interval, 0.988 to >0.999), respec
123 ultivariable-adjusted odds ratios were 1.35 (95 percent confidence interval, 0.99 to 1.84), 1.29 (95
124 plification testing were greater than 0.999 (95 percent confidence interval, 0.999 to >0.999) and 0.9
125 thods in the area under the ROC curve, 0.03; 95 percent confidence interval, -0.02 to 0.08; P=0.18).
126 and 1.0 for placebo (mean difference, -0.3; 95 percent confidence interval, -0.5 to -0.1; P=0.004).
127 w rate (mean difference, 0.43 ml per minute; 95 percent confidence interval, -0.52 to 1.38), prostate
128 n AUASI scores (mean difference, 0.04 point; 95 percent confidence interval, -0.93 to 1.01), maximal
130 ose in the high-dose group (risk ratio, 1.2; 95 percent confidence interval, 1.0 to 1.5; P=0.06).
131 .0 percent vs. 0.5 percent; risk ratio, 3.7; 95 percent confidence interval, 1.0 to 13.5; P=0.03).
133 were not capped; the odds ratios were 1.05 (95 percent confidence interval, 1.00 to 1.09), 1.13 (1.0
134 0.66 to 0.87; P<0.001) at 2 years and 1.14 (95 percent confidence interval, 1.00 to 1.31; P=0.05) at
135 troke (59 vs. 39 events; hazard ratio, 1.49; 95 percent confidence interval, 1.00 to 2.24; absolute r
138 e interval, 0.46 to 0.82; P=0.001) and 1.35 (95 percent confidence interval, 1.02 to 1.78; P=0.04).
139 similar among white women (risk ratio, 1.05; 95 percent confidence interval, 1.03 to 1.07) and black
140 pitalization for stroke (hazard ratio, 1.06; 95 percent confidence interval, 1.03 to 1.09), congestiv
141 e emergency department (relative rate, 1.09 [95 percent confidence interval, 1.04 to 1.14]), nonelect
142 higher among black women (risk ratio, 1.11; 95 percent confidence interval, 1.06 to 1.16) and was un
143 usted risk ratio per 10-mm2 increment, 1.18; 95 percent confidence interval, 1.06 to 1.30; P<0.01), t
144 lism (103 vs. 71 events; hazard ratio, 1.44; 95 percent confidence interval, 1.06 to 1.95; absolute r
145 ongestive heart failure (hazard ratio, 1.12; 95 percent confidence interval, 1.07 to 1.16), hip fract
146 ith the homeostatic model (odds ratio, 1.12; 95 percent confidence interval, 1.07 to 1.18 for each ad
147 n in the placebo group (relative risk, 1.40; 95 percent confidence interval, 1.07 to 1.83; P=0.02).
148 with those in the lowest quintile, was 1.41 (95 percent confidence interval, 1.07 to 1.86; P for tren
149 s twice as high (incidence-rate ratio, 2.01; 95 percent confidence interval, 1.08 to 3.75; P=0.03) as
152 group; risk ratio for each comparison, 1.9; 95 percent confidence interval, 1.1 to 3.2; P=0.02 for e
153 ar events (risk ratio for the low dose, 2.6; 95 percent confidence interval, 1.1 to 6.1; and risk rat
155 to 1.16), hip fracture (hazard ratio, 1.15; 95 percent confidence interval, 1.11 to 1.18), psychiatr
157 8), psychiatric disease (hazard ratio, 1.19; 95 percent confidence interval, 1.12 to 1.26), or dement
159 on with stroke or death (hazard ratio, 1.97; 95 percent confidence interval, 1.12 to 3.48; P=0.01).
160 to 0.93) for a BMI of less than 20.0, 1.38 (95 percent confidence interval, 1.13 to 1.67) for a BMI
161 59; and 80 to 180 days: relative risk, 1.27; 95 percent confidence interval, 1.14 to 1.41) and in all
162 ferative changes without atypia and of 1.27 (95 percent confidence interval, 1.15 to 1.41) for nonpro
163 and 7.9 percent; physical inactivity, 1.20 (95 percent confidence interval, 1.16 to 1.24) and 6.8 pe
164 weight and obese subjects (odds ratio, 1.55; 95 percent confidence interval, 1.16 to 2.08), as was ea
165 isk associated with seafood intake was 1.51 (95 percent confidence interval, 1.17 to 1.95; P for tren
166 cent, respectively; cigarette smoking, 1.23 (95 percent confidence interval, 1.18 to 1.27) and 7.9 pe
167 rately attenuated the relative risk to 1.68 (95 percent confidence interval, 1.18 to 2.38; P for tren
168 to 1.78; 40 to 79 days: relative risk, 1.37; 95 percent confidence interval, 1.19 to 1.59; and 80 to
169 years of age or older (relative risk, 1.51; 95 percent confidence interval, 1.19 to 1.92) and among
170 ); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008).
171 yocardial infarction--1.4 percent per month (95 percent confidence interval, 1.2 to 1.6 percent)--and
172 with female sex (adjusted hazard ratio, 1.7; 95 percent confidence interval, 1.2 to 2.4) and having o
175 han were CC homozygotes (hazard ratio, 1.55; 95 percent confidence interval, 1.20 to 2.01; P<0.001).
176 er in the placebo group (hazard ratio, 1.81; 95 percent confidence interval, 1.21 to 2.70; P=0.004) t
177 onfidence interval, 0.96 to 1.72), and 2.37 (95 percent confidence interval, 1.22 to 4.61), respectiv
178 2003; the respective odds ratios were 1.30 (95 percent confidence interval, 1.23 to 1.38), 1.27 (1.1
179 e-point increase in the BODE score was 1.34 (95 percent confidence interval, 1.26 to 1.42; P<0.001),
180 tudied (< or =180 days: relative risk, 1.37; 95 percent confidence interval, 1.27 to 1.49; <40 days:
181 e with levels of less than 1.0 mg per liter (95 percent confidence interval, 1.27 to 2.51; P for tren
184 rcent confidence interval, 0.9 to 3.7), 2.5 (95 percent confidence interval, 1.3 to 4.8), and 2.8 (95
185 or death from any cause (hazard ratio, 2.24; 95 percent confidence interval, 1.30 to 3.86; P=0.004).
186 h from any cause (adjusted risk ratio, 2.90; 95 percent confidence interval, 1.33 to 6.32; P<0.01), d
187 to die as men with persistent GBV-C viremia (95 percent confidence interval, 1.34 to 5.76; P=0.006).
188 x coronary-artery surgery (odds ratio, 2.59; 95 percent confidence interval, 1.36 to 4.95) or primary
189 1.27 to 1.49; <40 days: relative risk, 1.56; 95 percent confidence interval, 1.37 to 1.78; 40 to 79 d
191 eased inversely with the estimated GFR: 1.4 (95 percent confidence interval, 1.4 to 1.5), 2.0 (95 per
193 among those receiving placebo was 2.4 times (95 percent confidence interval, 1.4 to 4.2) that among t
194 t confidence interval, 1.3 to 4.8), and 2.8 (95 percent confidence interval, 1.4 to 5.4), respectivel
196 of the height in meters] below 18.5), 1.47 (95 percent confidence interval, 1.42 to 1.53) and 5.2 pe
197 tivariate relative risks of death were 1.55 (95 percent confidence interval, 1.42 to 1.70) for lean a
198 factors were as follows: hypertension, 1.48 (95 percent confidence interval, 1.44 to 1.53) and 11.7 p
199 sk of breast cancer for the cohort was 1.56 (95 percent confidence interval, 1.45 to 1.68), and this
200 for death from respiratory causes was 1.62 (95 percent confidence interval, 1.48 to 1.77; P<0.001).
204 tment period (mean difference, 6.62 percent; 95 percent confidence interval, 1.6 to 11.7; P=0.02), wh
205 that was not of extended duration, were 2.3 (95 percent confidence interval, 1.6 to 3.3) and 5.9 (95
206 to 1.70) for lean and inactive women, 1.91 (95 percent confidence interval, 1.60 to 2.30) for women
208 ), as compared with a relative risk of 1.88 (95 percent confidence interval, 1.66 to 2.12) for prolif
209 rval, 4.8 to 15.6) and at two weeks (6.1 mm; 95 percent confidence interval, 1.7 to 10.5) and returne
210 e times as high (incidence-rate ratio, 5.35; 95 percent confidence interval, 1.72 to 16.64; P=0.004)
211 congenital malformations (risk ratio, 2.71; 95 percent confidence interval, 1.72 to 4.27) as compare
212 s early period (rate, 2.3 percent per month; 95 percent confidence interval, 1.8 to 2.8 percent).
213 re severe irresponsibility (odds ratio, 8.5; 95 percent confidence interval, 1.8 to 40.1) and severel
215 13 to 1.67) for a BMI of 22.5 to 24.9, 2.20 (95 percent confidence interval, 1.81 to 2.66) for a BMI
217 the cardiovascular system (risk ratio, 3.72; 95 percent confidence interval, 1.89 to 7.30) and the ce
218 rcent confidence interval, 1.4 to 1.5), 2.0 (95 percent confidence interval, 1.9 to 2.1), 2.8 (95 per
219 umococcal disease (adjusted odds ratio, 2.4; 95 percent confidence interval, 1.9 to 3.1) as compared
220 behavior in medical school (odds ratio, 3.0; 95 percent confidence interval, 1.9 to 4.8), for a popul
221 81 to 2.66) for a BMI of 25.0 to 27.4, 2.43 (95 percent confidence interval, 1.96 to 3.01) for a BMI
222 m cardiac causes (adjusted risk ratio, 5.21; 95 percent confidence interval, 1.98 to 14.40; P<0.01),
223 e change from baseline scores was 0.1 point (95 percent confidence interval, -1.4 to 1.1; P=0.86).
225 il arsenic concentrations (odds ratio = 2.1, 95 percent confidence interval: 1.4, 3.3; p-trend = 0.00
227 AID doses made up by coxibs by 15.0 percent (95 percent confidence interval, 10.9 to 19.2 percent), c
228 7 percent; absolute difference, 2.4 percent; 95 percent confidence interval, -10.2 to 15.1 percent).
229 130 controls (35 percent) (odds ratio, 19.6; 95 percent confidence interval, 11.0 to 34.9) for whom d
231 rimary end point (risk reduction, 1 percent [95 percent confidence interval, -13 to 13 percent]).
232 absolute difference, -7.9 percentage points; 95 percent confidence interval, -16.4 to 0.7 percentage
233 nt of that associated with a spouse's death (95 percent confidence interval, 17 to 27 percent); for w
234 that in the monotherapy group (22.9 percent [95 percent confidence interval, 17.5 to 29.1 percent] vs
236 index of 30 or higher) but active, and 2.42 (95 percent confidence interval, 2.14 to 2.73) for inacti
238 ssociated with weight gain (odds ratio, 4.2; 95 percent confidence interval, 2.2 to 8.2), a racing ti
239 o 3.62) for a BMI of 30.0 to 34.9, and 2.93 (95 percent confidence interval, 2.24 to 3.85) for a BMI
241 significantly increased (odds ratios, 2.39 [95 percent confidence interval, 2.31 to 2.46] and 3.69 [
242 96 to 3.01) for a BMI of 27.5 to 29.9, 2.92 (95 percent confidence interval, 2.35 to 3.62) for a BMI
244 rcent confidence interval, 1.9 to 2.1), 2.8 (95 percent confidence interval, 2.6 to 2.9), and 3.4 (95
245 comparison with a time of <3:30 hours, 7.4; 95 percent confidence interval, 2.9 to 23.1), and body-m
246 improve FEV1 (mean difference, 2.9 percent; 95 percent confidence interval, -2.2 to 8.0; P=0.23).
247 rate was 28.6 percent in the placebo group (95 percent confidence interval, 20.3 to 38.6 percent) an
248 9.2 percent in the methylprednisolone group (95 percent confidence interval, 20.8 to 39.4 percent; P=
249 val, 23.2 to 42.0 percent) and 31.5 percent (95 percent confidence interval, 22.8 to 41.7 percent; P=
250 ); at 180 days, the rates were 31.9 percent (95 percent confidence interval, 23.2 to 42.0 percent) an
252 s of the end point with clopidogrel therapy (95 percent confidence interval, 24 to 47 percent; P<0.00
253 han subjects whose benefits were not capped (95 percent confidence interval, 29 to 33 percent) but ha
255 d cardiac events (adjusted risk ratio, 5.66; 95 percent confidence interval, 3.07 to 10.56; P<0.01).
256 t confidence interval, 2.6 to 2.9), and 3.4 (95 percent confidence interval, 3.1 to 3.8), respectivel
257 lative risk associated with atypia was 4.24 (95 percent confidence interval, 3.26 to 5.41), as compar
258 isk of a motor vehicle crash by 9.1 percent (95 percent confidence interval, 3.4 to 14.7 percent) and
259 confidence interval, 2.31 to 2.46] and 3.69 [95 percent confidence interval, 3.60 to 3.77], respectiv
262 risk, and high-risk groups were 6.8 percent (95 percent confidence interval, 4.0 to 9.6), 14.3 percen
263 n score on a visual-analogue scale, 10.2 mm; 95 percent confidence interval, 4.8 to 15.6) and at two
265 y; P=0.69; absolute difference, 1.1 percent; 95 percent confidence interval, -4.4 to 6.6 percent), as
266 thnic group was increased by 80+/-19 microm (95 percent confidence interval, 43 to 116; P<0.001) amon
268 nt confidence interval, 1.6 to 3.3) and 5.9 (95 percent confidence interval, 5.4 to 6.3), respectivel
269 solute difference of 16.7 percentage points (95 percent confidence interval, 5.6 to 27.9 percentage p
270 val, 17.5 to 29.1 percent] vs. 10.8 percent [95 percent confidence interval, 5.7 to 18.1 percent], P=
271 cases per 100,000 (a decline of 57 percent; 95 percent confidence interval, 55 to 58 percent) and fr
272 cases per 100,000 (a decline of 59 percent; 95 percent confidence interval, 58 to 60 percent), respe
273 ielding a prevented fraction of 100 percent (95 percent confidence interval, -62 to 100 percent).
275 orresponding to a decrease of 10.28 dollars (95 percent confidence interval, 7.56 dollars to 13.00 do
276 uring the commute from work by 16.2 percent (95 percent confidence interval, 7.8 to 24.7 percent).
277 nce was thus -2.6 ml per minute per 1.73 m2 (95 percent confidence interval, -7.1 to 2.0 ml per minut
279 fidence interval, 4.0 to 9.6), 14.3 percent (95 percent confidence interval, 8.3 to 20.3), and 30.5 p
282 val, 92.5 to 95.4 percent) and 90.6 percent (95 percent confidence interval, 88.7 to 92.2 percent), r
283 ical group (absolute difference, 12 percent; 95 percent confidence interval, 9 to 16 percent) by day
284 t delaying care (adjusted odds ratio, 12.65; 95 percent confidence interval, 9.45 to 16.94), as were
285 ntial new cancers prevented) of 100 percent (95 percent confidence interval, 90 to 100 percent).
286 onary embolism at 90 days were 94.1 percent (95 percent confidence interval, 92.5 to 95.4 percent) an
287 on at six months (with an upper bound of the 95 percent confidence interval around the treatment diff
288 r quintiles 2-5 were 1.4, 1.4, 1.4, and 1.6 (95 percent confidence interval (CI): 1.1, 2.2; p for tre
289 than one head injury (odds ratio (OR) = 3.1, 95 percent confidence interval (CI): 1.2, 8.1) and patie
290 tegory, hazard ratios among women were 1.47 (95 percent confidence interval [CI], 1.33 to 1.62) for a
291 antly between the two groups; on most tests, 95 percent confidence intervals excluded a 3-point (0.2
292 cent and 27.5 percent, respectively (P=0.48; 95 percent confidence interval for the difference betwee
293 rcent in the liberal-strategy group (P=0.30; 95 percent confidence interval for the difference, -2.6
294 a vs. 20.7 percent after systemic analgesia; 95 percent confidence interval for the difference, -9.0
295 percent in the zidovudine-lamivudine group; 95 percent confidence interval for the difference, 2 to
296 up (84 percent vs. 73 percent, respectively; 95 percent confidence interval for the difference, 4 to
297 58 cells per cubic millimeter, respectively; 95 percent confidence interval for the difference, 9 to
298 group (P=0.95; upper limit of the one-sided 95 percent confidence interval for this difference, 0.06
299 h the first quintile, the hazard ratios (and 95 percent confidence intervals) for death were as follo
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。